Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment

Yao Ma,Jiaxuan Han,Jinjun Jiang,Zhiwei Zheng,Yandi Tan,Chaoqi Liu,Yun Zhao

DOI: https://doi.org/10.1016/j.lfs.2020.118565

IF: 6.78

2020-12-01

Life Sciences

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>Anti-PD-L1 monoclonal antibody (mAb)-conjugated ultrasound (US) lipid-shelled microbubbles (PD-L1-MBs) were successfully synthesized to investigate whether that PD-L1-MBs could enhance anti-tumor effect in combination therapy with cisplatin (CDDP) under ultrasound mediation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main methods</h3><p>Based on affinity between biotin and streptavidin, we prepared microbubbles conjugated with anti-PD-L1 mAb by membrane hydration and mechanical oscillation. A subcutaneous tumor model was established to test the anti-tumor effect and immunological activity of this combination therapy. Bax and Bcl-2 expression were detected by RT-qPCR and Immunohistochemistry. Cells undergoing apoptosis in tissue section were determined by TUNEL. Proliferation of splenocytes was analyzed by Flow cytometry. A cytotoxic T lymphocyte assay was performed by CTL. Expression of PD-L1 and CD8 in tissue section was examined by immunologfluorescence. Expression of IFN-γ, TNF-α, CD86 and CD80 was also detected by RT-qPCR.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Key findings</h3><p>We observed that the growth of the subcutaneous tumor was significantly slower in combined group than that in the group treated with either drug or microbubbles. Moreover, higher antitumor activity was observed in the combined group than that in cisplatin alone, which could be reflected by the number of apoptotic cells in tumor tissues and over expression of bax in the combined group. This combination treatment also exhibited a better immunological activity, increasing the infiltration of CD8⁺ T cells and the expression of several revelant cytokines.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>The ultrasound lipid-shelled PD-L1-MBs may enhance anti-tumor effects of cisplatin by blocking the PD-L1 site and improving immune function.</p>

pharmacology & pharmacy,medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the immunosuppressive effect caused by the chemotherapeutic drug cisplatin in the treatment of cervical cancer, and how to enhance the anticancer effect of cisplatin and improve immune function by combining ultrasound microbubble technology and anti - PD - L1 monoclonal antibody (anti - PD - L1 mAb). Specifically, the researchers synthesized an ultrasound lipid - shelled microbubble (PD - L1 - MBs) combined with anti - PD - L1 monoclonal antibody and explored the therapeutic effect of this combination therapy on a cervical cancer xenograft tumor model under the mediation of ultrasound.

### Main research purposes:
1. **Enhance anti - tumor effect**: By combining anti - PD - L1 monoclonal antibody with ultrasound microbubbles, the researchers hope that, under the mediation of ultrasound, drugs can be more effectively delivered to the tumor site, thereby enhancing the anticancer effect of cisplatin.
2. **Reduce immunosuppression**: Although cisplatin has an anti - tumor effect, it may also up - regulate the expression of PD - L1 on the surface of tumor cells, leading to immunosuppression. The researchers hope to block the PD - L1/PD - 1 pathway, reduce the immunosuppressive effect caused by cisplatin, and improve the anti - tumor ability of the immune system.
3. **Improve treatment safety**: Through the ultrasound - mediated targeted delivery technology, reduce systemic toxicity and improve the safety and effectiveness of treatment.

### Research methods:
- **Microbubble preparation**: Prepare microbubbles using the thin - film hydration method and connect the anti - PD - L1 monoclonal antibody to the microbubble surface through biotin - avidin interaction.
- **In vitro experiments**: Verify the targeted aggregation ability and binding efficiency of microbubbles through techniques such as cell culture and immunofluorescence.
- **In vivo experiments**: Establish a mouse cervical cancer xenograft tumor model and evaluate the anti - tumor effects of different treatment groups (control group, blank microbubble + ultrasound, PD - L1 - MBs + ultrasound, cisplatin + ultrasound, combined treatment + ultrasound).
- **Molecular mechanism research**: Detect the expression levels of apoptosis - related proteins (such as Bax and Bcl - 2) and immune - related factors (such as IFN - γ, TNF - α, CD86, CD80) in tumor tissues, as well as the infiltration of CD8+ T cells through techniques such as RT - qPCR, immunohistochemistry, and TUNEL staining.

### Main findings:
- **Anti - tumor effect**: The tumor growth inhibition rate in the combined treatment group (PD - L1 - MBs + cisplatin + ultrasound) was the highest, which was 69.18% (volume) and 68.80% (mass) respectively, significantly higher than the groups treated with cisplatin or microbubbles alone.
- **Immunomodulation**: The combined treatment group not only enhanced the apoptosis of tumor cells, but also increased the infiltration of CD8+ T cells and the expression of multiple immune - related factors, indicating that it has a better immune activation effect.
- **Mechanism exploration**: Cisplatin may cause immunosuppression by up - regulating the expression of PD - L1, and the use of anti - PD - L1 microbubbles can effectively block this pathway and restore the anti - tumor function of the immune system.

In conclusion, this study proposes a new combined treatment strategy. Through the ultrasound - mediated anti - PD - L1 microbubble delivery technology, it not only enhances the anti - tumor effect of cisplatin, but also improves immune function, providing new ideas for the treatment of cervical cancer.